Citigroup Inc Compass Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 74,281 shares of CMPX stock, worth $101,764. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,281

Previous 23,131 221.13%

Holding current value

$101,764

Previous $23,000 491.3%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.8 - $1.88 $40,920 - $96,162	51,150 Added 221.13%	74,281 $136,000
Q2 2024 Aug 12, 2024	BUY	$1.0 - $1.85 $6,089 - $11,264	6,089 Added 35.73%	23,131 $23,000
Q1 2024 May 10, 2024	BUY	$1.2 - $2.29 $4,368 - $8,335	3,640 Added 27.16%	17,042 $33,000
Q4 2023 Feb 09, 2024	BUY	$1.4 - $1.98 $18,506 - $26,173	13,219 Added 7223.5%	13,402 $20,000
Q3 2023 Nov 09, 2023	SELL	$1.87 - $3.25 $54,052 - $93,941	-28,905 Reduced 99.37%	183 $0
Q2 2023 Aug 10, 2023	SELL	$2.64 - $3.48 $300,571 - $396,208	-113,853 Reduced 79.65%	29,088 $92,000
Q1 2023 May 11, 2023	BUY	$3.14 - $5.48 $52,205 - $91,110	16,626 Added 13.16%	142,941 $467,000
Q4 2022 Feb 09, 2023	BUY	$2.55 - $5.41 $310,544 - $658,840	121,782 Added 2686.57%	126,315 $635,000
Q3 2022 Nov 10, 2022	BUY	$1.9 - $3.37 $6,009 - $10,659	3,163 Added 230.88%	4,533 $10,000
Q2 2022 Aug 10, 2022	BUY	$1.43 - $3.1 $1,959 - $4,247	1,370 New	1,370 $4,000
Q1 2022 May 12, 2022	SELL	$1.25 - $3.5 $47,292 - $132,419	-37,834 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$2.88 - $3.98 $108,961 - $150,579	37,834 New	37,834 $120,000

Others Institutions Holding CMPX

# of Institutions

Shares Held

91.9M

Call Options Held

Put Options Held

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $139M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account